Evaluation the Effect of Adding Galantamine to Second Generation Antipsychotics

Evaluation the Effect of Adding Galantamine to Second Generation Antipsychotics, on Negative Symptoms of Schizophrenia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181117041682N2

Enrollment

Registered

2019-03-10

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: In the case group in addition use of second-generation anti-psychoactive agent Galantamin is added. initially, prescribing gallantamine will begin with a dose of

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Diagnosis of schizophrenia based on the DSM-5 Age of 18-55 years Get at least one second-generation anti-psychotic drug within the dose range Having a score of at least 15 in the subgroup of negative marks on the PANSS assessment scale

Exclusion criteria

Exclusion criteria: Other disorders in axis 1 The presence of cardiac disorders, liver disorders, kidney disorders and etc. History of allergy to second-generation antipsychotics Positive test for amphetamines or methamphetamines at initiate time of admission Pregnancy or breastfeeding Simultaneous treatment with anticholinergic drugs The existence of suicidal thoughts

Design outcomes

Primary

Measure	Time frame
Negative sign of Schizophrenia. Timepoint: at the start of treatment, weeks 2, 4 and 8 of treatment. Method of measurement: Oveall scale score PANS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Fakhri

Ahvaz University of Medical Sciences

Dr.fakhri@gmil.com+98 61 3374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026